«Congressional Brain Injury Task Force Newsletter | Home | Survey of State Medicaid Waiver Programs»

FDA Seeks New Warning for Epilepsy Drugs

Roughly 2.7 million Americans have epilepsy, according to government estimates and many forms of epilepsy are caused by a traumatic brain injury. 

The Food and Drug Administration is recommending a  "black box" warning about the risk of suicidal thoughts and behavior with epilepsy drugs, just days ahead of an advisory panel meeting.

The FDA in a memo said that the warning would apply to all epilepsy drugs.

A black box warning is the strongest type of warning that the FDA can compel a drug manufacturer to insert on a product.

Some of the tops selling epilepsy medication that can be affected by the warning are GlaxoSmithKline Plc's Lamictal,  Pfizer Inc's Lyrica, Johnson & Johnson's Topamax and Abbott Laboratories Inc's Depakote.

Read the full FDA epilepsy briefing document.



TrackBack URL for this entry:
Trackback link

Listed below are links to weblogs that reference FDA Seeks New Warning for Epilepsy Drugs:


The comments to this entry are closed.